NeoGenomics

NeoGenomics Laboratories, Inc.
Company type
Public
Nasdaq: NEO
S&P 600 Component
Russell 2000 Component
IndustryBiotechnology, Health care
Founded2002; 24 years ago (2002)
Headquarters
Fort Myers, Florida
,
United States
Number of locations
13
Area served
Worldwide
Key people
Tony Zook (CEO)
Lynn A. Tetrault (Chair of the Board)
ServicesCancer genetics diagnostic testing
Revenue$500M
Number of employees
2200 (2025)
Websiteneogenomics.com

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.[1]

Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.[2]

History

NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.

In 2013, the company launched its sequencing platform[3] and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.[4][5]

In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare.[6][7] Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.[8]

In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.[9]

In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.[10]

References

  1. ^ "Standardizing Biomarker Analysis Across Clinical Testing". Technology Networks. Retrieved 8 October 2017.
  2. ^ Hogan, Dick. "Fort Myers company buys cancer test provider for $275M". The News-Press. Retrieved 8 October 2017.
  3. ^ Mansell, Peter (19 November 2013). "Covance, NeoGenomics ally on CT testing services". PharmaTimes. Retrieved 8 October 2017.
  4. ^ "NeoGenomics Launches Two New Cancer Tests". FDAnews. Retrieved 8 October 2017.
  5. ^ "Lee-based NeoGenomics cancer research company acquires California lab". Naples Daily News. Retrieved 8 October 2017.
  6. ^ Wasserman, Robert (6 July 2016). "NeoGenomics deal with GE's Clarient 6 months later: boom or bust?". TheStreet. Retrieved 8 October 2017.
  7. ^ Stynes, Tess (21 October 2015). "NeoGenomics to Acquire GE Cancer Testing Unit Clarient". Wall Street Journal. Retrieved 8 October 2017.
  8. ^ Lawrence, Stacy. "Small cap NeoGenomics to buy GE cancer diagnostics biz Clarient for $300M". FierceBiotech. Retrieved 8 October 2017.
  9. ^ Nikolic, Dejan. "L'américain NeoGenomics installe son siège européen à Rolle". Le Temps (in French). Retrieved 8 October 2017.
  10. ^ "Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase". Natera. Retrieved 2025-04-21.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.